Artiva Biotherapeutics Files IPO Amendment

TL;DR

Artiva Biotherapeutics filed an S-1/A for its IPO. Get ready for potential new biotech stock.

AI Summary

Artiva Biotherapeutics, Inc. filed an S-1/A amendment on July 15, 2024, for its initial public offering. The company, incorporated in Delaware, is seeking to register an unspecified number of shares. The filing details its principal executive offices at 5505 Morehouse Drive, San Diego, CA 92121, with Fred Aslan, M.D., serving as President and CEO.

Why It Matters

This S-1/A filing indicates Artiva Biotherapeutics is moving forward with its plan to become a publicly traded company, which could provide it with capital for research and development or expansion.

Risk Assessment

Risk Level: medium — Biotechnology companies often carry higher risks due to the inherent uncertainties in drug development and regulatory approval processes.

Key Numbers

• 28 — Public Document Count (Indicates the volume of documents associated with this filing.)
• 863614316 — IRS Number (The company's Employer Identification Number.)

Key Players & Entities

• Artiva Biotherapeutics, Inc. (company) — Registrant
• July 15, 2024 (date) — Filing date
• Fred Aslan, M.D. (person) — President and Chief Executive Officer
• 5505 Morehouse Drive, Suite 100 San Diego, CA 92121 (address) — Principal executive offices
• 333-280568 (registration_number) — SEC registration number

FAQ

Key Financial Figures

• $14.00 — l public offering price will be between $14.00 and $16.00 per share of our common stoc
• $16.00 — fering price will be between $14.00 and $16.00 per share of our common stock. We have
• $160 billion — for which in 2023 reached approximately $160 billion and represent the second-largest class
• $1 million — an incremental financial burden of over $1 million per patient. The scalability of our pro
• $100,000 — acture auto-CAR-Ts is estimated at over $100,000 per treatment course, limiting flexibil
• $6,000 — AlloNKs COGS per patient would be below $6,000, an order of magnitude below the curren

Filing Documents

• d808948ds1a.htm (S-1/A) — 2712KB
• d808948dex11.htm (EX-1.1) — 259KB
• d808948dex31.htm (EX-3.1) — 111KB
• d808948dex51.htm (EX-5.1) — 9KB
• d808948dex104.htm (EX-10.4) — 168KB
• d808948dex107.htm (EX-10.7) — 76KB
• d808948dex108.htm (EX-10.8) — 13KB
• d808948dex231.htm (EX-23.1) — 3KB
• d808948dexfilingfees.htm (EX-FILING FEES) — 16KB
• g808948g01a56.jpg (GRAPHIC) — 684KB
• g808948g01t47.jpg (GRAPHIC) — 147KB
• g808948g05d70.jpg (GRAPHIC) — 84KB
• g808948g0710232633070.jpg (GRAPHIC) — 2KB
• g808948g10h74.jpg (GRAPHIC) — 145KB
• g808948g14b15.jpg (GRAPHIC) — 148KB
• g808948g23r23.jpg (GRAPHIC) — 155KB
• g808948g48g01.jpg (GRAPHIC) — 8KB
• g808948g48g02.jpg (GRAPHIC) — 4KB
• g808948g48g49.jpg (GRAPHIC) — 227KB
• g808948g57f34.jpg (GRAPHIC) — 102KB
• g808948g58e83.jpg (GRAPHIC) — 651KB
• g808948g60a01.jpg (GRAPHIC) — 125KB
• g808948g60a03.jpg (GRAPHIC) — 122KB
• g808948g60a05.jpg (GRAPHIC) — 112KB
• g808948g65l36.jpg (GRAPHIC) — 108KB
• g808948g68c46.jpg (GRAPHIC) — 115KB
• g808948g80l03.jpg (GRAPHIC) — 65KB
• g808948g90s40.jpg (GRAPHIC) — 690KB
• 0001193125-24-178806.txt ( ) — 8390KB

RISK FACTORS

RISK FACTORS 13 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 79 INDUSTRY AND OTHER DATA 81 DIVIDEND POLICY 82

USE OF PROCEEDS

USE OF PROCEEDS 83 CAPITALIZATION 85

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 90

BUSINESS

BUSINESS 112 MANAGEMENT 169 EXECUTIVE AND DIRECTOR COMPENSATION 177 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 195 PRINCIPAL STOCKHOLDERS 200

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 203 SHARES ELIGIBLE FOR FUTURE SALE 208 MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S. HOLDERS 210

UNDERWRITING

UNDERWRITING 214 LEGAL MATTERS 223 EXPERTS 223 WHERE YOU CAN FIND MORE INFORMATION 223 INDEX TO FINANCIAL STATEMENTS F-1 We and the underwriters have not authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses we have prepared. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may provide you. We are offering to sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of the common stock. For investors outside the United States: Neither we nor the underwriters have done anything that would permit this offering, or the possession or distribution of this prospectus, in any jurisdiction where action for those purposes is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, this offering of common stock and the distribution of this prospectus outside the United States. Table of Contents PROSPECTUS SUMMARY This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our common stock. Before investing in our common stock, you should read this entire prospectus carefully, especially the sections titled Risk Factors, Special Note Regarding Forward-Looking Statements, and Managements Discussion and Analysis of Financial Condition and Results of Operations, and our financial statements and the related notes appearing elsewhere in this prospectus. As used in this prospectus, unless the context ot

View Full Filing

View this S-1/A filing on SEC EDGAR